Stockscreener 앱 받기
63.98
4.49%
2.75
전일 마감가:
$61.23
열려 있는:
$62.43
하루 거래량:
7.83M
Relative Volume:
1.62
시가총액:
$24.69B
수익:
$4.66B
순이익/손실:
$836.30M
주가수익비율:
30.57
EPS:
2.093
순현금흐름:
$1.08B
1주 성능:
-0.06%
1개월 성능:
-4.96%
6개월 성능:
-3.93%
1년 성능:
-6.69%
1일 변동 폭
$61.90
$64.09
1주일 범위
$60.82
$64.09
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
63.98 | 23.63B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
96.81 | 165.90B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
343.32 | 129.59B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.19 | 109.96B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.23 | 94.25B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.99 | 45.58B | 6.07B | 1.06B | 1.34B | 1.8063 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
KBC Group NV Sells 133,500 Shares of DexCom, Inc. $DXCM - MarketBeat
Chicago Capital LLC Reduces Position in DexCom, Inc. $DXCM - MarketBeat
TransMedics & Dexcom: Healthcare Stocks for Long-Term GrowthNews and Statistics - IndexBox
A Look at DexCom Inc (DXCM) After 4.5% Gain -- GF Value $109.11 vs Price $63.98 - GuruFocus
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom EVP Brown sells $107k in shares - Investing.com
Dexcom (DXCM) EVP sells 1,700 shares, still holds 111,204 - Stock Titan
Here's Why You Should Add DexCom Stock to Your Portfolio Now - Yahoo Finance
DexCom, Inc. $DXCM Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
DEXCOM INC ($DXCM) President & CEO 2025 Pay Revealed - Quiver Quantitative
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
[ARS] DEXCOM INC SEC Filing - Stock Titan
Dexcom (NASDAQ: DXCM) posts growth, seeks votes on board, pay and auditor - Stock Titan
Michael Brown (DXCM) files Form 144 to sell 1,700 restricted shares - Stock Titan
DexCom (DXCM) Upgraded to Buy: Here's Why - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Sells 15,977 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Dexcom Inc. stock (US2521311074): Why does its continuous glucose monitoring edge matter more now? - AD HOC NEWS
Dexcom Inc. stock (US2521311074): Why does its CGM leadership matter more now for U.S. investors? - AD HOC NEWS
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to unlock new upsid - AD HOC NEWS
Here's Why DexCom (DXCM) is a Strong Growth Stock - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
BTIG Research Adjusts DexCom Price Target to $80 From $85, Maintains Buy Rating - marketscreener.com
DexCom Salaries - Comparably
Greenup Street Wealth Management Invests in DexCom - National Today
Greenup Street Wealth Management LLC Makes New Investment in DexCom, Inc. $DXCM - MarketBeat
Risk Analysis: Can DexCom Inc be the next market leader2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Trend Recap: Can DexCom Inc be the next market leaderPortfolio Profit Report & High Accuracy Trade Alerts - baoquankhu1.vn
Wells Fargo Maintains DexCom (DXCM) Overweight Recommendation - MSN
DexCom (XSWX:DXCM) Other Assets for Banks - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to drive U.S. inves - AD HOC NEWS
DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy - ChartMill
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
DexCom (DXCM) Is Up 5.5% After New G7 Reimbursement Wins And CEO Transition PlansWhat's Changed - Sahm
DXCM (DexCom) Future Policy Benefits - GuruFocus
Alert from law firm on Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DXCM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Goldman Sachs Adjusts Price Target on DexCom to $82 From $83, Maintains Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Shareholders to Connect - ACCESS Newswire
At US$63.21, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Devon Energy Corp stock: Merger clearance sparks scale questions for investors - AD HOC NEWS
Rathbones Group PLC Sells 18,632 Shares of DexCom, Inc. $DXCM - MarketBeat
Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nisa Investment Advisors Reduces DexCom Stake by Over 50% - National Today
Nisa Investment Advisors LLC Sells 20,529 Shares of DexCom, Inc. $DXCM - MarketBeat
Aberdeen Group plc Acquires 43,990 Shares of DexCom, Inc. $DXCM - MarketBeat
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.65%
자본화:
|
볼륨(24시간):